News

Filter

Current filters:

Humira

51 to 60 of 96320 results

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Horizon Discovery acquires Sage Labs for $48 million

Horizon Discovery acquires Sage Labs for $48 million

29-09-2014

UK-based Horizon Discovery Group has agreed to acquire Sage Labs of the USA for up to $16 million in…

GeneticsHorizon DiscoveryMergers & AcquisitionsPharmaceuticalSage LabsUKUSA

Sigmoid in licensing deal with Pendopharm for CyCol in Canada

Sigmoid in licensing deal with Pendopharm for CyCol in Canada

29-09-2014

Irish drug delivery technology company Sigmoid Pharma has entered into agreements with Canada’s Pendopharm,…

CanadaCyColFinancialGastro-intestinalsLicensingPendopharmPharmaceuticalPharmascienceSigmoid Pharma

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Update: Negotiations on EU-Canada Free Trade Agreement concluded

Update: Negotiations on EU-Canada Free Trade Agreement concluded

29-09-2014

Canadian trade group Research-Based Pharmaceutical Companies (Rx&D) expressed its support to the government…

CanadaEuropeGenericsMarkets & MarketingPatentsPoliticsRegulation

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

Moshe Manor appointed president and chief executive of Protalix BioTherapeutics

Moshe Manor appointed president and chief executive of Protalix BioTherapeutics

29-09-2014

Israeli pharma company Protalix BioTherapeutics has appointed Moshe Manor as its new president and chief…

BoardroomIsraelPharmaceuticalPresident and chief executiveProtalix BioTherapeutics

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

51 to 60 of 96320 results

Back to top